TheKB1
Posted - 5 hours ago
$BHVN weak retail hands while institutions and insiders load up. How the rich get richer 😬
tomRussell80
Posted - 6 hours ago
$BHVN down $25 bucks within weeks 👌👌
Dallas21
Posted - 7 hours ago
$BHVN approaching 50 percent drop territory. WHAT THE FUCK IS THE NEWS?
sellthedip1
Posted - 8 hours ago
$BHVN would love to see 19 again 😂
TheKB1
Posted - 10 hours ago
$BHVN picking up more shares here. Interesting swing trading opportunity coming with their R&D day in May
moneybags4ever
Posted - 11 hours ago
$BHVN I really don’t understand what happened that we dropped $20.. hope this thing turns around quickly
speakmannameonlyonce
Posted - 1 day ago
$BHVN still say this goes lower, but who who knows?
Tormod
Posted - 1 day ago
$BHVN Weve been brutally raaped
PensionPulse
Posted - 1 day ago
$BHVN Boy was I spot on!
PensionPulse
Posted - 1 day ago
$BHVN Great timing for stock offering!
knowthyself
Posted - 1 day ago
$BHVN Hits $40 and I'll buy.
OpenOutcrier
Posted - 1 day ago
$BHVN (-4.1% pre) Biohaven Pharma (BHVN) Prices 5.6M Share Offering at $41/sh - SI https://ooc.bz/l/30706
DonCorleone77
Posted - 1 day ago
$BHVN Biohaven 5.609M share Spot Secondary priced at $41.00 The deal size was increased to $230M in common stock from $200M in common stock and the range was $40.50-$42.00. JPMorgan acted as sole book running manager for the offering.
Stock_Titan
Posted - 1 day ago
$BHVN Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
https://www.stocktitan.net/news/BHVN/biohaven-announces-pricing-of-230-million-public-offering-of-common-c87pki0zfab2.html
TheKB1
Posted - 2 days ago
$BHVN From the SEC Filing: “Vlad Coric, our Chief Executive Officer, and certain of our directors and their affiliated funds have indicated an interest in purchasing up to $62,000,000, in the aggregate, of our common shares in this offering at the public offering price. Dr. Coric has indicated an interest in purchasing approximately $5,000,000 of the common shares being offered hereby. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, fewer or no shares to each of Dr. Coric or our directors and their affiliated funds, and any of such persons or their affiliated funds could determine to purchase more, fewer or no shares in this offering.”
mikesterz7
Posted - 2 days ago
$BHVN Biohaven Pharma declined 3% after it commenced an underwritten public offering of $200 million of its common shares.
xbibackto70s
Posted - 2 days ago
$BHVN fing joke mgmt diluting as always! F bios
DonCorleone77
Posted - 2 days ago
$BHVN Biohaven $200M Spot Secondary; price range $40.50-$42.00 JPMorgan is acting as sole book running manager for the offering.
Stock_Titan
Posted - 2 days ago
$BHVN Biohaven Announces Proposed Public Offering of Common Shares
https://www.stocktitan.net/news/BHVN/biohaven-announces-proposed-public-offering-of-common-wmkolo8vak1k.html
TheKB1
Posted - 2 days ago
$BHVN Having worked as a physician for the past 20 years and having traded biotechs for 25+ years, Biohaven's current pipeline is among the most impressive that I have seen and has the potential to significantly impact large, currently underserved patient populations. This is a stock you buy and HOLD. Vlad and his team are proven, and this will be a buyout target. VERY
Dallas21
Posted - 2 days ago
$BHVN so still nothing to explain a 20 percent loss? Got it
PensionPulse
Posted - 3 days ago
$BHVN Will retest $37, my hunch, tough environment for biotechs...
Dallas21
Posted - 3 days ago
$BHVN seriously wtf is going on here
Aigner_Andreas
Posted - 3 days ago
TF SELL $BHVN at 44.77 : 49.54 MidCap 98% Shp 1.98 S 3.35 N 0.7 RSI 32.58% SRSI 0% ADXR 26.62 #stocks #trading #finance #market
TheKB1
Posted - 3 days ago
$BHVN if you have money on the sidelines, this is the time to pick up more shares. Very very
Quantumup
Posted - 4 days ago
Baird $BHVN Outperform/$58: ‘‘Initial IgG degrader update leaves investors salivating for more. It sounds like the company is leaving the juice for their May 29 R&D day, but the initial teaser indicates both a clean initial safety profile and IgG lowering that is, 'consistent with modeling based on nonclinical experience.' What exactly that means is open to interpretation and, we believe, will likely be debated for the next month and a half. The absence of full details for such a highly anticipated data point is likely to lead to speculation that there is something wrong with the results. However, even in the one slide update, there looks like there is enough information to eliminate the major risk factors: safety and/or subpar activity. Also, we don't see the incentive to save poor data for a major promotional event for the company. With an initial 16 subjects through two dosing cohorts, we think this is an encouraging update but see the real meat in the May 29 update.’’
Birchbranch
Posted - 4 days ago
$BHVN "On Monday, Piper Sandler maintained its Overweight rating and $66.00 stock price target for Biohaven Pharmaceutical Holding (NYSE:BHVN), despite a significant delay in the release of specific trial data. The delay pertains to the disclosure of Single Ascending Dose (SAD) data for BHV-1300, a novel pan-IgG degrader. The company decided to postpone progressing to the next dose cohorts to fully understand the longer-term follow-up. Biohaven management's discussions reveal that the IgG lowering effects observed are in line with preclinical models. Although no data were presented today, the management's commentary suggests that the IgG reduction is consistent with expectations. The full details are anticipated to be unveiled at the company's R&D Day on May 29th, and the firm continues to recommend the stock to buyers."
DonCorleone77
Posted - 4 days ago
$BHVN Biohaven presents update on Phase 1 single ascending dose study for BHV-1300 In a regulatory filing, Biohaven disclosed that David Spiegel, M.D. Ph.D., inventor of Biohaven's MoDE technology and Professor of Chemistry at Yale University, will present an update on Biohaven's degrader platform and summary of progress to date in the Phase 1 single ascending dose, or "SAD," study for BHV-1300 at the ABI Conference 2024 in Cambridge, United Kingdom starting April 15. A copy of the presentation was disclosed by the company in the filing with the SEC.
thayford
Posted - 4 days ago
$BHVN glad I trimmed at 56
